We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

This study has been terminated.
(Study due for continuing review)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00899132
First Posted: May 12, 2009
Last Update Posted: September 29, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center
  Purpose

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.


Condition Intervention
Non-melanomatous Skin Cancer Pancreatic Cancer Small Intestine Cancer Testicular Germ Cell Tumor Genetic: in situ hybridization Genetic: protein expression analysis Other: immunologic technique

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: The Role of TAB3 Protein in Tumorigenesis

Resource links provided by NLM:


Further study details as provided by Case Comprehensive Cancer Center:

Primary Outcome Measures:
  • Identification of TAB3 transcript/protein as a molecular marker of cancer [ Time Frame: end of study ]
  • Characterization of TAB3 and its signaling networks that are involved in tumorigenesis [ Time Frame: end of study ]

Biospecimen Retention:   Samples With DNA
Tumor tissue samples from paraffin-embedded tissue blocks.

Enrollment: 180
Study Start Date: February 2007
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Genetic: in situ hybridization
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
    Genetic: protein expression analysis
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
    Other: immunologic technique
    Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
Detailed Description:

OBJECTIVES:

  • To identify TAB3 transcript/protein as a molecular marker of cancer, specifically testicular, skin, small intestine, and pancreatic cancer.
  • To characterize TAB3 and its signaling networks that are involved in tumorigenesis.

OUTLINE: Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary care center
Criteria

DISEASE CHARACTERISTICS:

  • Paraffin tissue blocks from surgical pathology cancer cases, specifically testicular, skin, small intestine, and pancreatic cancer, available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00899132


Locations
United States, Ohio
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States, 44106-5065
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Ge Jin, PhD Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
  More Information

Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00899132     History of Changes
Other Study ID Numbers: CASE5Y06
P30CA043703 ( U.S. NIH Grant/Contract )
CASE5Y06 ( Other Identifier: Case Comprehensive Cancer Center )
CASE-5Y06-CC191 ( Other Identifier: Cancer Center IRB )
First Submitted: May 9, 2009
First Posted: May 12, 2009
Last Update Posted: September 29, 2015
Last Verified: September 2015

Keywords provided by Case Comprehensive Cancer Center:
skin cancer
small intestine cancer
pancreatic cancer
malignant testicular germ cell tumor
testicular teratoma

Additional relevant MeSH terms:
Pancreatic Neoplasms
Neoplasms, Germ Cell and Embryonal
Skin Neoplasms
Testicular Neoplasms
Intestinal Neoplasms
Duodenal Neoplasms
Ileal Neoplasms
Jejunal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Neoplasms by Histologic Type
Skin Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Testicular Diseases
Gonadal Disorders
Gastrointestinal Neoplasms
Gastrointestinal Diseases
Intestinal Diseases
Duodenal Diseases
Ileal Diseases
Jejunal Diseases